Pfizer in talks to transition EpiPen maker into generics spinoff: spokeswoman
July 29, 2019
Sterling tumbles on hard Brexit worries; stocks slip
July 29, 2019

Pfizer to spinoff, merge off-patent drugs unit with Mylan

Pfizer Inc has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV , a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar.

Powered by WPeMatico